PKA

PKA
Name	Protein kinase A
Uniprot	P17612 / Q9Y2X0 / Q9HCP0
Organism	Homo sapiens

PKA Protein kinase A is a cAMP-dependent serine/threonine kinase central to intracellular signaling. It transduces signals from G protein-coupled receptors and second-messenger systems to regulate metabolism, transcription, and cell fate. PKA integrates cues from hormonal axes and stress pathways to coordinate responses in tissues such as liver, heart, brain, and immune organs.

Introduction

Protein kinase A operates as a tetrameric holoenzyme composed of regulatory and catalytic subunits that respond to fluctuating cyclic adenosine monophosphate levels produced by adenylyl cyclases downstream of receptors such as β-adrenergic receptor, glucagon receptor, and vasopressin receptor. The kinase participates in pathways involving adenylate cyclase, G protein alpha_s subunit, phosphodiesterase‎ regulation, and cross-talk with kinases like AMP-activated protein kinase, PKC, and ERK1/2. Historically, PKA studies intersect with work by researchers at institutions including Rockefeller University, Harvard Medical School, and Cold Spring Harbor Laboratory that characterized cyclic nucleotide signaling.

Structure and Isoforms

Mammalian PKA catalytic subunits include isoforms encoded by genes such as PRKACA, PRKACB, and PRKACG; regulatory subunits include RIα (PRKAR1A), RIβ (PRKAR1B), RIIα (PRKAR2A), and RIIβ (PRKAR2B). Crystal structures resolved by groups affiliated with RCSB PDB and investigators at Max Planck Society reveal a bilobed kinase domain homologous to the catalytic cores of protein kinase B, MAP kinase, and other eukaryotic protein kinases. The holoenzyme architecture shows dimeric regulatory subunits that bind two catalytic monomers, and AKAP family scaffolds such as AKAP79, AKAP95, and AKAP7 target holoenzymes to subcellular locales including mitochondria, centrosomes, and synapses studied by teams at University of California, San Diego and University College London.

Activation Mechanism and Regulation

Activation begins when extracellular ligands engage receptors like thyrotropin-releasing hormone receptor or parathyroid hormone receptor, stimulating adenylate cyclase to convert ATP to cAMP. cAMP binds regulatory subunits, inducing conformational changes that release active catalytic subunits which then phosphorylate substrates including transcription factors such as CREB, metabolic enzymes such as glycogen synthase kinase 3 beta, and ion channels such as the L-type calcium channel. Negative regulation occurs via phosphodiesterase 4, protein phosphatase 1, ubiquitin ligases characterized by work at European Molecular Biology Laboratory, and genetic controls identified in studies from National Institutes of Health. Crosstalk with insulin receptor signaling, feedback through mTORC1, and compartmentalized cAMP microdomains defined by AKAP interactions shape PKA output.

Biological Functions and Signaling Pathways

PKA controls glycogen metabolism via phosphorylation of glycogen synthase and phosphorylase kinase, regulates lipolysis through hormone-sensitive lipase in adipocytes, modulates cardiac contractility via troponin I and phospholamban, and influences neuronal plasticity by phosphorylating AMPA receptor subunits and CREB to affect memory circuits studied at Massachusetts Institute of Technology and Stanford University. In endocrine systems, PKA mediates actions of adrenocorticotropic hormone, thyroid-stimulating hormone, and follicle-stimulating hormone signaling in glands like the adrenal cortex and thyroid gland. Developmental and cell-cycle roles involve interactions with Wnt signaling, Hedgehog signaling, and regulators such as p53 and cyclin D1. PKA also participates in immune modulation, affecting pathways downstream of receptors such as Toll-like receptor 4 and cytokines like interleukin-6.

Clinical Significance and Disease Associations

Germline and somatic mutations in PRKAR1A and PRKACA are implicated in disorders including Carney complex, cortisol-producing adrenal adenomas, and certain Cushing syndrome subtypes; oncogenic fusions involving PRKACA have been described in fibrolamellar hepatocellular carcinoma. Dysregulated PKA signaling contributes to cardiac arrhythmias observed in long QT syndrome studies, metabolic conditions such as type 2 diabetes mellitus through effects on hepatic gluconeogenesis, and neuropsychiatric disorders where PKA-CREB signaling is altered in research from National Institute of Mental Health. Pharmacologic modulation has clinical relevance: drugs targeting GPCRs like propranolol and albuterol or enzymes such as phosphodiesterase inhibitors influence PKA activity; PKA pathway components are explored in trials at centers including Mayo Clinic and Johns Hopkins Hospital.

Experimental Methods and Assays

Common experimental approaches include in vitro kinase assays using radioactive ATP or fluorescence-based substrates developed in laboratories at Cold Spring Harbor Laboratory and EMBL. cAMP measurements employ enzyme immunoassays and FRET-based biosensors such as Epac-based sensors used by teams at Imperial College London. Structural studies utilize X-ray crystallography and cryo-EM performed with facilities at Diamond Light Source and EMBL-EBI. Genetic manipulation uses CRISPR/Cas9 methodologies popularized from work at Broad Institute and transgenic mouse models generated at The Jackson Laboratory to probe tissue-specific functions. Clinical assays include immunohistochemistry and sequencing panels at diagnostic centers like Molecular Diagnostics Laboratory at major academic hospitals.

Category:Protein kinases Category:Signal transduction